ClinicalTrials.gg
CompletedNCT02288325Updated Oct 29, 2018Results posted

A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder

A Phase 4 interventional study of Levomilnacipran ER and Placebo in Depressive Disorder, Major, sponsored by Forest Laboratories. Completed at 47 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-10-29.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
644
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing levomilnacipran in Depressive Disorder, Major — none open to participants now, none under way, none of them phase 3. Levomilnacipran · Depressive Disorder, Major.

Enrollment
4th of 14
644 · median 472
Started
2014
the only one that year
Phase 4
3 of 14
none open now
Registered
8th of 14
by date
Lead sponsor
9 of 14
Forest Laboratories

Among the 14 studies testing levomilnacipran in Depressive Disorder, Major, this one is the 4th largest by enrollment, is the only one that started in 2014, is one of 3 in phase 4, and was the 8th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

None of the 14 studies testing levomilnacipran in Depressive Disorder, Major is open now. The open studies under Depressive Disorder, Major, anywhere →

Where they have run

About levomilnacipran

Levomilnacipran: first FDA approval 2013 (FETZIMA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing levomilnacipran in Depressive Disorder, Major as a file.
02

Study summary

This study evaluates the efficacy, safety and tolerability of levomilnacipran extended-release (ER) compared with placebo in the prevention of depression relapse in major depressive disorder (MDD).

03

Conditions studied

  • Depressive Disorder, Major

Keywords

  • Fetzima
  • Relapse-prevention
  • Placebo-controlled
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently meet the DMS-5 (, 5th edition) criteria for Major Depressive Disorder (MDD)
  • The participant must have an ongoing major depressive episode of at least 8 weeks and no more than 18 months
  • The participant must have at least 3 lifetime episodes of MDD (including the current episode)

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant, women who will be breastfeeding during the study, and women with who are not practicing a reliable method of
  • Participants who are considered a suicide risk
  • History of non-response to 2 or more antidepressants (after adequate treatment)
  • Participants who have a history of meeting DMS-5 criteria for manic, hypomanic, or mixed episode, obsessive-compulsive disorder, schizophrenia or other psychotic disorder
  • Panic disorder
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
644 participants (actual)

Study arms

  • Experimental
    Open-Label FETZIMA®

    FETZIMA® (levomilnacipran extended release \[ER\]) taken orally during flexible dose titration up to 40, 80 or 120 mg once daily in 8-week run-in period followed by fixed dose of 40, 80 or 120 mg once daily in 12-week stabilization period.

    Drug: Levomilnacipran ER

  • Placebo comparator
    Double-Blind Placebo

    Dose-matched placebo taken orally once daily for 26 weeks during double-blind treatment period.

    Drug: Placebo

  • Experimental
    Double-Blind FETZIMA®

    FETZIMA® (levomilnacipran ER) taken orally at fixed dose of 40, 80 or 120 mg once daily for 26 weeks during double-blind treatment period.

    Drug: Levomilnacipran ER

Interventions

  • Levomilnacipran ER taken orally at 40, 80 or 120 mg once daily.

    Also known as: FETZIMA®

  • DrugPlacebo

    Dose-matched placebo taken orally once daily.

06

What researchers measure

Primary outcomes

  1. Time to First Relapse During the Double-Blind Treatment Period (DBTP)

    Time to relapse for the median was measured in days from randomization date at the start of the DBTP to relapse date during DBTP. Relapse was defined as meeting any 1 or more of the following criteria: 1) Insufficient therapeutic response at any one visit, including a \>/= 2 increase in Clinical Global Impressions-Severity (CGI-S) score (range 1 to 7) compared with that obtained at randomization, or risk of suicide as determined by the investigator, or need for hospitalization due to worsening of depression as determined by the investigator, or need for alternative treatment of depressive symptoms as determined by the Investigator; 2) Montgomery-Asberg Depression Rating Scale (MADRS) total score \>/= 18 (range 0 to 60) at 2 consecutive visits (second visit within 7 to 14 days after the first visit at which the MADRS total score was ≥ 18). Participant was considered censored at the last visit during DBTP if participant did not meet the relapse criteria during DBTP.

    Time frame: From the randomization date (Week 20) to the relapse date during the 26-week DBTP (up to Week 46)

07

Results

Posted Oct 29, 2018

Participant flow

Run-in Period
Participant flow — Run-in Period
MilestoneOpen-Label FETZIMA®Double-Blind PlaceboDouble-Blind FETZIMA®
Started64400
Completed49900
Not completed14500
Withdrew: Adverse event4800
Withdrew: Lack of efficacy1600
Withdrew: Withdrawal of consent2800
Withdrew: Lost to follow-up2500
Withdrew: Protocol violation1700
Withdrew: Non-compliance with study drug300
Withdrew: Reason not specified800
Stabilization Period
Participant flow — Stabilization Period
MilestoneOpen-Label FETZIMA®Double-Blind PlaceboDouble-Blind FETZIMA®
Started42900
Completed33100
Not completed9800
Withdrew: Adverse event1300
Withdrew: Lack of efficacy2200
Withdrew: Withdrawal of consent2300
Withdrew: Lost to follow-up1200
Withdrew: Protocol violation800
Withdrew: Non-compliance with study drug500
Withdrew: Reason not specified1500
Double-blind Treatment Period
Participant flow — Double-blind Treatment Period
MilestoneOpen-Label FETZIMA®Double-Blind PlaceboDouble-Blind FETZIMA®
Started0159165
Completed0135139
Not completed02426
Withdrew: Adverse event025
Withdrew: Withdrawal of consent088
Withdrew: Lost to follow-up045
Withdrew: Protocol violation012
Withdrew: Non-compliance with study drug014
Withdrew: Multiple reasons082

Outcome measures

PrimaryTime to First Relapse During the Double-Blind Treatment Period (DBTP)

Time to relapse for the median was measured in days from randomization date at the start of the DBTP to relapse date during DBTP. Relapse was defined as meeting any 1 or more of the following criteria: 1) Insufficient therapeutic response at any one visit, including a \>/= 2 increase in Clinical Global Impressions-Severity (CGI-S) score (range 1 to 7) compared with that obtained at randomization, or risk of suicide as determined by the investigator, or need for hospitalization due to worsening of depression as determined by the investigator, or need for alternative treatment of depressive symptoms as determined by the Investigator; 2) Montgomery-Asberg Depression Rating Scale (MADRS) total score \>/= 18 (range 0 to 60) at 2 consecutive visits (second visit within 7 to 14 days after the first visit at which the MADRS total score was ≥ 18). Participant was considered censored at the last visit during DBTP if participant did not meet the relapse criteria during DBTP.

Time frame:
From the randomization date (Week 20) to the relapse date during the 26-week DBTP (up to Week 46)
Reported as:
Median · days
Time to First Relapse During the Double-Blind Treatment Period (DBTP)
daysDouble-Blind PlaceboDouble-Blind FETZIMA®
Time to First Relapse During the Double-Blind Treatment Period (DBTP)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Double-Blind Placebo vs Double-Blind FETZIMA® · Log Rank · p = 0.0212 · Hazard ratio (hr): 0.56 · 95% CI 0.33 to 0.92

Adverse events

Collected over Up to 48 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open-Label FETZIMA®0/644 (0%)9/644 (1.4%)430/644 (66.8%)
Double-Blind Placebo0/159 (0%)1/159 (0.6%)29/159 (18.2%)
Double-Blind FETZIMA®0/165 (0%)2/165 (1.2%)41/165 (24.8%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventOpen-Label FETZIMA®Double-Blind PlaceboDouble-Blind FETZIMA®
OverdoseInjury, poisoning and procedural complications0/6441/1590/165
Transient ischaemic attackNervous system disorders0/6440/1591/165
Escherichia pyelonephritisInfections and infestations0/6440/1591/165
Panic attackPsychiatric disorders1/6440/1590/165
Oesophageal squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/6440/1590/165
MigraineNervous system disorders1/6440/1590/165
ManiaPsychiatric disorders1/6440/1590/165
InfluenzaInfections and infestations1/6440/1590/165
HyponatraemiaMetabolism and nutrition disorders1/6440/1590/165
Gastrointestinal haemorrhageGastrointestinal disorders1/6440/1590/165
Most frequent other events
Showing 10 of 12
Most frequent other events
EventOpen-Label FETZIMA®Double-Blind PlaceboDouble-Blind FETZIMA®
NauseaGastrointestinal disorders174/6445/15913/165
HeadacheNervous system disorders103/64412/15917/165
Heart rate increasedInvestigations71/6444/1594/165
ConstipationGastrointestinal disorders69/6443/1593/165
Upper respiratory tract infectionInfections and infestations46/64410/15916/165
HyperhidrosisSkin and subcutaneous tissue disorders57/6442/1591/165
DizzinessNervous system disorders50/6444/1591/165
TachycardiaCardiac disorders50/6443/1596/165
NasopharyngitisInfections and infestations25/6447/15911/165
Dry mouthGastrointestinal disorders37/6442/1590/165

Baseline characteristics

Run-in Phase (RIP) Safety Population comprised all participants in the screened population who took at least 1 dose of open-label levomilnacipran during the RIP.

Age, Continuous
Age, Continuous(years)Open-Label FETZIMA®
Mean43.1 ± 13.9
Sex: Female, Male
Sex: Female, Male(Participants)Open-Label FETZIMA®
Female404
Male240
08

Study locations

47 sites
  • Forest Investigative Site 053
    Birmingham, Alabama 35294, United States
  • Forest Investigative Site 050
    Dothan, Alabama 36303, United States
  • Forest Investigative Site 039
    Phoenix, Arizona 85032, United States
  • Forest Investigative Site 048
    Beverly Hills, California 90210, United States
  • Forest Investigative Site 047
    Chino, California 91710, United States
  • Forest Investigative Site 028
    Costa Mesa, California 92626, United States
  • Forest Investigative Site 021
    Encino, California 91316, United States
  • Forest Investigative Site 052
    Lemon Grove, California 91945, United States
  • Forest Investigative Site 042
    Oceanside, California 92056, United States
  • Forest Investigative Site 016
    Sherman Oaks, California 91403, United States
  • Forest Investigative Site 037
    Sherman Oaks, California 91403, United States
  • Forest Investigative Site 043
    Simi Valley, California 93065, United States
  • Forest Investigative Site 040
    Cromwell, Connecticut 06475, United States
  • Forest Investigative Site 038
    Norwich, Connecticut 06360, United States
  • Forest Investigative Site 023
    Bradenton, Florida 34201, United States
  • Forest Investigative Site 018
    Fort Myers, Florida 33912, United States
  • Forest Investigative Site 008
    Jacksonville Beach, Florida 32250, United States
  • Forest Investigative Site 001
    Jacksonville, Florida 32256, United States
  • Forest Investigative Site 057
    Kissimmee, Florida 34741, United States
  • Forest Investigative Site 009
    Orlando, Florida 32801, United States
  • Forest Investigative Site 045
    West Palm Beach, Florida 33407, United States
  • Forest Investigative Site 034
    Alpharetta, Georgia 30005, United States
  • Forest Investigative Site 049
    Smyrna, Georgia 30080, United States
  • Forest Investigative Site 019
    Schaumburg, Illinois 60194, United States
  • Forest Investigative Site 020
    Methuen, Massachusetts 01844, United States
  • Forest Investigative Site 051
    Watertown, Massachusetts 02472, United States
  • Forest Investigative Site 044
    Cherry Hill, New Jersey 08002, United States
  • Forest Investigative Site 031
    Brooklyn, New York 11235, United States
  • Forest Investigative Site 036
    Cedarhurst, New York 11516, United States
  • Forest Investigative Site 013
    Mount Kisco, New York 10549, United States
  • Forest Investigative Site 003
    New York, New York 10003, United States
  • Forest Investigative Site 005
    New York, New York 10168, United States
  • Forest Investigative Site 055
    Rochester, New York 14618, United States
  • Forest Investigative Site 058
    Charlotte, North Carolina 28211, United States
  • Forest Investigative Site 011
    Dayton, Ohio 45417, United States
  • Forest Investigative Site 035
    Tulsa, Oklahoma 74104, United States
  • Forest Investigative Site 046
    Portland, Oregon 97210, United States
  • Forest Investigative Site 041
    Salem, Oregon 97301, United States
  • Forest Investigative Site 012
    Media, Pennsylvania 19063, United States
  • Forest Investigative Site 030
    Memphis, Tennessee 38119, United States
  • Forest Investigative Site 033
    Memphis, Tennessee 38119, United States
  • Forest Investigative Site 054
    Dallas, Texas 75243, United States
  • Forest Investigative Site 059
    Houston, Texas 77090, United States
  • Forest Investigative Site 014
    Murray, Utah 84123, United States
  • Forest Investigative Site 010
    Charlottesville, Virginia 22911, United States
  • Forest Investigative Site 056
    Roanoke, Virginia 24014, United States
  • Forest Investigative Site 026
    Brown Deer, Wisconsin 53223, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Sep 2016, 21 months.

Results were first posted in Oct 2018, 2 years 1 month after primary completion.

Of 98 phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2014
First posted
Nov 11, 2014
StartActual
Nov 18, 2014
Primary completionActual
Sep 16, 2016
CompletionActual
Sep 16, 2016
Results first posted
Oct 29, 2018
Last update
Oct 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02288325
Responsible party
Sponsor
First posted
Nov 11, 2014
Start date
Nov 18, 2014
Primary completion
Sep 16, 2016
Completion
Sep 16, 2016
Results posted
Oct 29, 2018
Last update
Oct 29, 2018

Study contacts

Raffaele Migliore
study director · Forest Research Institute, Inc., an affiliate of Allergan, plc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levomilnacipran

Start the discussion